These data suggest that PM acts in two ways to promote early tumorigenesis: by increasing the number of EGFR mutant cells with the potential to form a tumour and by increasing the proliferation rate of EGFR mutant cells within these early lesions. The gene discussed is EGFR; the disease is neoplasm.